The “Tooth Regrowth” Drug in Human Trials: What It Actually Is (and Isn’t) Yet

A few patients have brought me headlines over the past year asking some version of the same question: “should I just wait for the tooth regrowth drug instead of getting an implant?” It’s a fair thing to ask, because the coverage has been genuinely striking — a real pharmaceutical company, real human trials, and a real scientific mechanism behind it, not just a speculative lab experiment. But there’s a meaningful gap between what’s actually happening in these trials and what the more excitable headlines imply. Let me walk through the real science, where the research actually stands, and why it doesn’t change what I’d recommend to a patient sitting in my chair today.

How researchers stumbled onto this in the first place

The discovery behind this research has an unusual origin. In 2007, a research team led by Dr. Katsu Takahashi at Kyoto University encountered a mouse model with more teeth than normal — tooth buds that should have degenerated after the animal’s regular teeth developed had instead continued growing. Investigating why led the team to USAG-1, the protein responsible for normally shutting that growth down. That single observation in an unusual mouse became the foundation for over a decade of subsequent research, eventually leading to the antibody-based drug now in human trials.

It’s worth appreciating how long this timeline actually is, because it puts the current trial stage in perspective. Nearly two decades passed between the original mouse observation and the first human trial. A 2021 study published in the journal Science Advances provided the proof-of-concept demonstrating that targeting USAG-1 with a neutralizing antibody could trigger tooth regeneration directly, and it took several more years of additional animal work before regulators allowed the first human safety trial to begin. Genuinely novel drug mechanisms like this one don’t move quickly, even when the underlying science is compelling — and that pace is itself useful context for how to think about when this might realistically reach a broader patient population.

The science behind it

The drug at the center of this, known as TRG035, is being developed by Toregem BioPharma, a company spun out of Kyoto University research. The underlying science traces back to a discovery that humans, like most mammals, carry the dormant genetic blueprint for a third set of teeth — structures called tooth buds that typically degenerate quietly after your permanent teeth come in, rather than ever developing further. Researchers identified a protein called USAG-1 that actively suppresses this third set of tooth buds from growing. Research has shown that inhibiting USAG-1 facilitates tooth regeneration by activating the BMP and Wnt signaling pathways responsible for normal tooth development, and animal studies in mice and ferrets found that a single antibody injection blocking USAG-1 led to the growth of complete, functional teeth that integrated with existing dental structures.

That’s a genuinely different mechanism than anything currently used in dentistry — it isn’t a material, a graft, or a prosthetic. It’s a drug designed to reactivate a biological process your body already has the blueprint for, just switched off.

Where the human trials actually stand

This is the part that separates real, current science from years-away speculation, and it’s worth being precise about the timeline. A Phase 1 safety trial ran from late 2024 through 2025, enrolling adult men missing at least one molar, specifically to test safety rather than effectiveness at scale. As of early 2026, no serious adverse events had been reported, with a final report expected around mid-2026. A Phase 2 trial is planned to begin in the summer of 2026 at Kyoto University Hospital, enrolling a small group of children with a specific, severe genetic condition.

Who this treatment currently targets — and who it doesn’t

This is the single most important clarification, because it’s where the headlines tend to blur an important distinction. The trials underway right now are specifically targeting severe congenital hypodontia — a rare genetic condition where six or more permanent teeth never develop at all, affecting an estimated 600,000 people in Japan alone and a considerably larger number globally. The Phase 2 trial specifically enrolls children between ages 2 and 12 with this diagnosis.

This is not, at this stage, a treatment for the far more common situation my patients actually deal with: teeth lost to decay, gum disease, or trauma over the course of adult life. The company has stated that treating this kind of acquired tooth loss is part of its longer-range goal, but it’s explicitly a later phase of research, not something currently in human trials. The scientific rationale for adults is actually a bit different too — the current trials work by reactivating dormant tooth buds that failed to develop in children with a genetic condition, while any future application to adult tooth loss would need to demonstrate that the same third-set tooth buds, which humans are believed to retain in a dormant state even into adulthood, can be successfully reactivated decades after they would normally have degenerated. That’s a related but distinct scientific question from the one currently being tested, and it hasn’t yet been studied in human trials. The distinction matters enormously for anyone hoping this might apply to their own situation soon.

Why this shouldn’t change what you do today

I understand the appeal of waiting for a solution that sounds more like restoring your own natural tooth than replacing it with titanium and porcelain. But a few realities are worth weighing against that appeal. This treatment, even in the best-case scenario, is years away from being available for the condition it’s currently being tested on, and considerably further from being tested — let alone approved — for adult tooth loss from decay or gum disease. Implants, by contrast, have decades of research behind them, published survival rates consistently above 90% at the 10-year mark, and are available to you now, not on a hopeful multi-year timeline contingent on trials that haven’t started yet. A proven treatment available today reliably beats a promising one that may or may not be available, for your specific situation, a decade from now.

Delaying a needed extraction, implant, or bridge on the chance that a regenerative treatment might eventually apply to your situation risks the same problem that comes with any delayed dental care: more bone loss, more complexity, and a more difficult starting point if you eventually do need a proven treatment instead.

Questions this research tends to raise

“Could this eventually replace implants entirely?” It’s conceivable in the very long term, if research successfully expands beyond congenital conditions to acquired tooth loss and clears the full approval process, but that’s a genuinely distant possibility, not a near-term alternative to discuss with your dentist today.

“Is this available anywhere right now, even outside trials?” No. It exists only within the structure of clinical trials in Japan at this stage, and participation is limited to patients meeting very specific study criteria, not a treatment anyone can currently seek out.

“Why does the timeline matter so much here?” Because drug development has a well-established, lengthy path from promising early trials to approved treatment, and most experimental drugs that reach Phase 1 never make it to market at all. Phase 1 establishes safety in a small group; Phase 2 and Phase 3 need to demonstrate real effectiveness in progressively larger populations before any regulatory body will approve it for general use.

“Should I ask my dentist about this?” It’s a perfectly reasonable thing to be curious about, and I’m always glad to talk through where research like this actually stands. What it shouldn’t do is change the treatment plan for a tooth you need addressed now.

What would actually need to happen for this to reach patients broadly

Phase 2 and Phase 3 trials would need to succeed, first in the specific congenital population being studied now, demonstrating not just safety but genuine effectiveness at scale.

Regulatory approval would need to follow, in Japan first and separately in other countries, including the U.S., where only a preliminary Pre-IND conversation has happened so far — a meaningfully early step in a process that typically takes years even after successful trials.

Research would need to expand to acquired tooth loss specifically, which is a distinct scientific question from reactivating dormant tooth buds in a congenital condition, and hasn’t yet begun in human trials.

Manufacturing and distribution would need to scale, which is its own multi-year undertaking even after a drug is approved for its first indication.

How this compares to what’s actually available now

This is genuinely exciting, credible science — a real biological mechanism, a real company, and real human trials already underway, which is more than most “breakthrough” dental headlines can say. But it’s specifically aimed at a rare congenital condition in children right now, years away even for that population, and considerably further from being an option for the kind of adult tooth loss most patients actually face. It’s worth following with real interest, and I’ll gladly discuss where the research stands if you’re curious. It isn’t a reason to put off a conversation about implants, bridges, or any other proven treatment your dentist recommends today — those remain the right call for your mouth right now, regardless of how promising the research pipeline looks a few years down the road.